Tucotuzumab

Tucotuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Immunomedics.

History

Tucotuzumab was one of the many monoclonal antibodies developed for the treatment of cancer. It was developed by Immunomedics, a company that specializes in the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Mechanism of Action

As a monoclonal antibody, Tucotuzumab works by targeting and attaching to specific proteins on the surface of cancer cells. This allows the immune system to better recognize and attack these cells.

Clinical Trials

Tucotuzumab has undergone various clinical trials to test its effectiveness and safety in treating cancer. The results of these trials have contributed to the understanding of the drug's potential benefits and risks.

See Also

• Monoclonal antibodies
• Immunomedics
• Clinical trials

References

Tucotuzumab Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski